Cargando…
2650. Evaluating Antiviral Agents for Human Noroviruses Using a Human Intestinal Enteroid Model
BACKGROUND: Norovirus can cause chronic infections with serious morbidity and mortality in immunocompromised patients. While there are no FDA-approved medications for these infections, nitazoxanide, ribavirin, and enterally administered pooled immunoglobulin (IVIG) are used off-label on the basis of...
Autores principales: | Cortes-Penfield, Nicolas W, Ramani, Sasirekha, Neill, Frederick, Ettayebi, Khalil, Atmar, Robert, Estes, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809658/ http://dx.doi.org/10.1093/ofid/ofz360.2328 |
Ejemplares similares
-
A Standardized Antiviral Pipeline for Human Norovirus in Human Intestinal Enteroids Demonstrates No Antiviral Activity of Nitazoxanide
por: Lewis, Miranda A., et al.
Publicado: (2023) -
New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids
por: Ettayebi, Khalil, et al.
Publicado: (2021) -
Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges
por: Estes, Mary K., et al.
Publicado: (2019) -
Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation
por: Costantini, Veronica, et al.
Publicado: (2018) -
Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection
por: Haga, Kei, et al.
Publicado: (2020)